Simcere 
Welcome,         Profile    Billing    Logout  
 45 Products   258 Diseases  45 Products   463 Trials   9251 News 
586 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Iremod (iguratimod) / Simcere
NCT04981145: The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome

Recruiting
4
78
RoW
Iguratimod Tablets, Hydroxychloroquine Sulfate Tablets
Second Affiliated Hospital, School of Medicine, Zhejiang University
Primary Sjögren's Syndrome
12/24
07/25
NCT05803135: Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis

Not yet recruiting
4
138
NA
Iguratimod combined with Tofacitinib;, Placebo of Iguratimod combined with Tofacitinib
Nanfang Hospital of Southern Medical University, Jiangsu Simcere Pharmaceutical Co., Ltd.
Rheumatoid Arthritis
01/25
12/25
ChiCTR2000029112: A Multi-center, Randomized, Double-blind, Placebo-controlled Trial for the Efficacy and Safety of Iguratimod in Combination With Celecoxib in the Treatment of Ankylosing Spondylitis (AS) or Axial Spondyloarthritis (axSpA)

Recruiting
3
240
 
lguratimod plus NSAID ;placebo plus NSAID
Ruijin Hospital; Ruijin Hospital, Jiangsu Simcere Pharmaceuticals
Ankylosing Spondylitis /Axial Spondyloarthritis
 
 
NCT04830644: A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.

Recruiting
2
144
RoW
Iguratimod, Placebo
Jiangsu Simcere Pharmaceutical Co., Ltd.
Primary Sjögren Syndrome
04/22
06/22
NCT05281068: The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Recruiting
2
120
RoW
Iguratimod, Iremod, Danazol
Peking University People's Hospital, Beijing Hospital, China-Japan Friendship Hospital, Beijing Friendship Hospital, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Chongqing Medical University, Shanxi Bethune hospital, Shanxi, China
ITP, Immune Thrombocytopenia
09/23
12/23
ChiCTR1900021345: Effect of Iguratimod on Primary Sjogren's Syndrome

Recruiting
N/A
60
 
Hydrochloroquine ;Iguratimod
Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, China International Medical Exchange Foundation Simcere Clinical Research Project Fund
Primary Sjogren's Syndrome
 
 
Endostar (recombinant human endostatin) / Simcere
ChiCTR-TRC-10001187: Prospective, open, multicentre clinical trial (phase II) of Endostar(recombinant human endostatin) on combined radiotherapy and chemotherapy for esophageal cancer

Completed
4
60
 
Endostar: 7.5mg/m2, D1-D14, D21-35; for 2 cycles; Paclitaxel Injection: 175mg/m2, D1; DDP: 75-90mg/m2, D1; E=6MV, GTV-P: 60-66Gy/30-33every time/6~7w (2Gy-2.1/every time), CTVN-P: 51Gy/30 (1.7Gy/every time) ;Paclitaxel Injection: 175mg/m2, D1; DDP: 75-90mg/m2, D1; E=6MV, GTV-P: 60-66Gy/30-33every time/6-7w (2Gy-2.1/every time), CTVN-P: 51Gy/30 (1.7Gy/every time)
Fujian Provincial Tumor Hospital; Jiangsu Simcere pharmaceutical Co.Ltd, Jiangsu Simcere pharmaceutical Co.Ltd
ⅡB, III, IV esophageal cancer
 
 
ChiCTR-TRC-11001424: Search of TEC ally Endostar used in preoperative chemotherapy in breast cancer stage III

Completed
4
160
 
TEC ;TEC+ Endostar
Hebei Medical University Fourth Hospital; Hebei Medical University Fourth Hospital, self-funding
breast cancer
 
 
ChiCTR-TRC-12001891: randomized control trial of Endostar in deferent time combined with DP regime for IIIB-IV stage NSCLC

Completed
4
150
 
Endostar combined with DP regime in three different times
Nantong Tumor Hospital; Jiangsu Xiansheng Pharmaceutical Co., Ltd, Simcere Company
None Small Cell Lung Cancer
 
 
ChiCTR-ONRC-11001598: Phase II trial of Endostar combined with CHOPT for T cell lymphoma

Completed
4
30
 
Endostar combined with CHOPT regime
Tianjin Medical University Cancer Institute and Hospital; Jiangsu Xiansheng Pharmaceutical Co., Ltd, Simcere Company
T cell lymphoma
 
 
ChiCTR-TNRC-10000944: Clinical research on the theraputic effect of recombined human endostatin with interventional therapy for hepatic metastatic tumor from gastrointestinal tract

Completed
4
60
 
treated with only interventional therapy ;treated with rh-endostatin and interventional ther
NanJing Jinling Hospital; Simcere Pharmaceutical Industries Co., Ltd, simcere Pharmaceutical Industries Co., Ltd
hepatic metastatic tumor
 
 
ChiCTR-TRC-12002363: Clinical study of recombinant human endostatin in deferent time combined with paclitaxel and cisplatin in treatment of advanced none-small cell lung cancer

Completed
4
90
 
human endostatin 7.5mg/m2 + Cisplatin 175mg/m2 +TP 80mg/m2 iv in day 1 and three weeks repeat and total two cycles ;human endostatin 7.5mg/m2 for 14 days +TP 80mg/m2 iv in day 1 and + Cisplatin 175mg/m2 in day 5 five weeks repeat and total two cycles ;TP 80mg/m2 iv in day 1 and + Cisplatin 175mg/m2 in day 5 five weeks repeat and total two cycles
Sichuan Province Luzhou Medical College affiliated Hospital; Simcere Pharmaceutical Company, Simcere Pharmaceutical Company
None Small Cell Lung Cancer
 
 
ChiCTR-IPR-17011666: Effect of recombinant human endostatin on the clinical treatment of malignant cavity effusion

Completed
4
84
 
only given Endostar ;Endostar combined with cisplatin ;only treated with cisplatin
Medical Department of Dalian University; Affiliated Zhongshan Hospital of Dalian University, Wu Jieping Medical Foundation Clinical Research Special Project Fund
malignant cavity effusion
 
 
ChiCTR-ONRC-14004210: Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Completed
4
20
 
drug therapy
Beijing Tiantan Hospital Affiliated to Capital Medical University; Beijing Tiantan Hospital Affiliated to Capital Medical University, Shandong Simcere-Medgenn Bio-pharmaceutical Co.,Ltd.
Neurofibromatosis type 2
 
 
ChiCTR-IPR-16008803: The randomized controlled study of intrathoracic application of recombinant human endostatin single or combined with cisplatin for the treatment of malignant pleural effusion

Not yet recruiting
4
60
 
endostar monotherapy ;endostar combined cisplatin ;Cisplatin monotherapy
Chongqing Cancer Hospital; Chongqing cancer hospital, Chongqing cancer hospital
lung cancer
 
 
ChiCTR-IPR-16009926: Recombinant human endostatin (Endostar) continuous pump infusion combined with concurrent radiochemotherapy in patients with esophageal squamous cell cancer: a prospective, randomized controlled clinical study

Not yet recruiting
4
120
 
Endostar:15mg/d, continuous pump infusion within 1 week before radiotherapy, and then concurrent with radiothetapy (continuous pump infusion for 5 days, and then rest for 2 days), total 6 weeks. Radiotherapy: 3D-CRT/IMRT/IGRT; Involved field irradiation(IFI), GTV for esophageal primary tumor, GTVnd for metastatic lymph nodes,&; Radiotherapy: 3D-CRT/IMRT/IGRT; Involved field irradiation(IFI), GTV for esophageal primary tumor, GTVnd for metastatic lymph nodes, CTV as 3cm upward and 4cm downward of GTV; 95% prescription dose: PGTV 60-66Gy/30-33f, PTV 46-50Gy/23-25f.Chemotherapy: Docetaxel 60mg/m2, d1; Cisplatin 25mg/m2,d1-3; 21-28d/cycle, 2-4cycles.
Gansu Provincial Cancer Hospital; Gansu Provincial Cancer Hospital, Seif-financing
Esophageal cancer
 
 
ChiCTR-IPR-17010441: Human Recombinant Endostatin Injection Durative Transfusion Combined With Chemotherapy in The First-line Treatment of Advanced Lung Squamous Carcinoma

Recruiting
4
220
 
human recombinant human endostatin(endostar) injection combined with chemotheapy ;chemotheapy
The First Affiliated Hospital of Wannan Medical College; The First Affiliated Hospital of Wannan Medical College, self-financing
Squamous Cell Lung Cancer
 
 
ChiCTR2000040892: Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in treating patients with locally advanced cervical cancer

Completed
4
116
 
Cisplatin: 40 mg/m2 for 5 weeks; IMRT: PTV1 50-54 Gy; PTV2 45-48.6 Gy; PTV3 45-48.6 Gy; HDR brachtherapy: 24 Gy in 4 fractions ;Endostar 7.5 mg/m2/d from D1 to D14 for 2 cycles, starting on the first day of IMRT; Cisplatin: 40 mg/m2/w for 5 weeks; IMRT: PTV1 50-54 Gy; PTV2 45-48.6 Gy; PTV3 45-48.6 Gy; HDR brachtherapy: 24 Gy in 4 fractions
People's Hospital of Guangxi Zhuang Autonomous Region; People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Medical and Health Care Appropriate Technology Development and Promotion Program
Cervical cancer
 
 
ChiCTR-IPR-17011374: Human recombinant endostatin (Endostar) combined with concurrent radiochemotherapy in patients with cervical squamous cell cancer: a prospective, randomized controlled clinical study

Recruiting
4
100
 
Human recombinant endostatin (Endostar) combined with concurrent radiochemotherapy ;concurrent radiochemotherapy
The Cancer Hospital of Gansu Province; The Cancer Hospital of Gansu Province, Seif-financing
cervical cancer
 
 
ChiCTR1900021279: A clinical study for Endostar combined with TP regimen concurrent radiotherapy for esophageal cancer: a randomized controlled trial

Recruiting
4
80
 
Endostar+chemoradiotherapy ;Chemoradiotherapy
The Second Affiliated Hospital of Xi'an Jiaotong University; The Second Affiliated Hospital of Xi'an Jiaotong University, Self financing
Esophageal cancer
 
 
ChiCTR2000033802: Clinical trial of different administration of endostar in the treatment of advanced non-small cell lung cancer with malignant pleural effusion

Not yet recruiting
4
60
 
Intravenous drip endostar; perfusion endostar into pleural
Xinjiang Medical University Affiliated Oncology Hospital; Xinjiang Medical University Affiliated Oncology Hospital, No
Non small cell lung cancer
 
 
ChiCTR1800014879: Study on antiangiogenic transformation medicine of advanced colorectal cancer based on APE1 expression

Not yet recruiting
4
116
 
Endostar combined with FOLFOX ;FOLFOX
Daping Hospital, Chongqing; Daping Hospital，Chongqing, Project funding
Colorectal cancer
 
 
RELIEF, NCT04613284: Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC

Not yet recruiting
4
97
NA
Recombinant human endostatin (Endostar), Durvalumab, Thoracic irradiation of 50 Gy with 3DCRT or IMRT
Shanghai Chest Hospital, Wuhan University
Lung Cancer
02/22
08/23
ChiCTR1900024622: A multicenter, randomized controlled trial for ENDOSTAR intravenous infusion combined with AP/GP versus AP/GP for the first-line treatment of stage IIIB-IV-driven gene-negative lung adenocarcinoma and lung squamous cell carcinoma

Not yet recruiting
4
346
 
ENDOSTAR & AP ;AP ;ENDOSTAR & GP ;GP
Zhujiang Hospital of Southern Medical University; Zhujiang Hospital of Southern Medical University, Zhujiang Hospital of Southern Medical University
Lung cancer
 
 
ChiCTR2100053353: A trial of three-day continuous Osmotic Pump of endostar combined with platinum-based chemotherapy plus Sindilizumab? for treatment? advanced non-small-cell lung cancer

Not yet recruiting
4
20
 
three-day continuous Osmotic Pump of endostar combined with platinum-based chemotherapy plus Sindilizumab
Zigong First People's Hospital, Sichuan Province; Zigong First People's Hospital, Sichuan Province, Zigong First People's Hospital, Sichuan Province
lung caner
 
 
ChiCTR2100050095: A single-arm, multi-center, prospective clinical study of recombinant human endostatin injection combined with afatinib maleate tablets and Siggio capsules in the second-line treatment of advanced squamous cell carcinoma of the lung

Not yet recruiting
4
30
 
recombinant human endostatin injection combined with afatinib dimaleate tablets and tegafur, gimeracil and oteracil potassium capsules
The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, China International Medical Exchange Foundation - Simcere Clinical Research Special Fund
advanced lung squamous cell carcinoma
 
 
ChiCTR2200064150: Study of continuous intravenous infusion of rh-endostatin for three days in the combination chemotherapy of advanced NSCLC with negative driver gene mutation

Not yet recruiting
4
68
 
continuous intravenous infusion of rh-endostatin for three days in the combination chemotherapy
Shanghai General Hospital; Shanghai General Hospital, Shandong Simcere Bio-Pharmaceutical Co., Ltd.
Non-small cell lung cancer
 
 
ChiCTR2200060332: Concurrent chemoradiotherapy with or without recombinant human endostatin (Endo) consolidation with envafolimab in patients with stage III unresectable non-small cell lung cancer (NSCLC)

Not yet recruiting
4
72
 
The dose of Endostar is 7.5 mg/m2, continuous intravenous infusion 5 days a week, starting 5 days before radiotherapy, one cycle every 2 weeks, a total of 4 cycles. Synchronous EP program for 3 cycles. Consolidation therapy with enverolimab was started 14 days to 30 days after the end of radiotherap ;3 cycles of radiotherapy synchronous EP program. 14 days to 30 days after the end of radiotherapy, Envolimumab consolidation therapy was started, 400 mg each time, 28 days/time, until disease progression or intolerance, and the longest treatment time was 1 year.
Jiamusi Cancer Hospital; Jiamusi Cancer Hospital, China International Medical Foundation
Stage III unresectable non-small cell lung cancer
 
 
ChiCTR2100042088: Recombinant Human Endostatin Combined With Platinum-Containing Dual Drug for the First-Line Treatment of Driver Gene-Negative Advanced Non-Small Cell Lung Cancer: a Multicenter, Single-Arm Trial

Recruiting
4
100
 
Endostar (210mg, durative transfused for 120 hours) was administered every three weeks beginning on the first day of each treatment cycle. Carboplatin (AUC 5-6) or cisplatin (75mg/m2)+pemetrexed (500 mg/m2) Q3W with 4 cycles, followed by Endostar+ pemetrexed at the end of 4 cycles until disease progression or i ;Endostar (210mg, durative transfused for 120 hours) was administered every three weeks beginning on the first day of each treatment cycle. Carboplatin(AUC 5-6) or cisplatin (75 mg/m2)+Paclitaxel (175 mg/m2) Q3W with 4 cycles, followed by Endostar at the end of 4 cycles until disease progression or intolerable t
The First Affiliated Hospital of Shandong First Medical University; The First Affiliated Hospital of Shandong First Medical University, Self-financing
Advanced Non-small Cell Lung Cancer
 
 
ChiCTR2200064322: Study on the efficacy and safety of recombinant human endostatin combined with PD1 inhibitor and chemotherapy in the treatment of pancreatic cancer

Not yet recruiting
4
60
 
Endostar + Camrelizumab + Chemotherapy ;Chemotherapy
The Affiliated People's Hospital of Jiangsu University ; The Affiliated People's Hospital of Jiangsu University, China International Medical Exchange Foundation Xiansheng clinical research special fund
Pancreatic cancer
 
 
ChiCTR2300070009: A single-arm, exploratory clinical study of 3-day continuous intravenous pump of endostatin (endostar) combined with chemotherapy and immune checkpoint inhibitor in the treatment of advanced lung squamous cell carcinom

Not yet recruiting
4
30
 
3-day continuous intravenous pump of endostatin (endostar) combined with chemotherapy and immune checkpoint inhibiton
Yancheng First People's Hospital; Yancheng First People's Hospital, scientific research task
advanced lung squamous cell carcinom
 
 
NCT05782764: A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom

Recruiting
4
30
RoW
To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV)., Endostar combined with immune checkpoint inhibitor and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV)
Xuzhou Medical University
Lung Squamous Cell Carcinoma
05/25
05/25
ChiCTR2400085777: A multicenter real-world study on the efficacy and safety of recombinant human endostatin combined with chemotherapy and PD-1/PD-L1 first-line treatment in non-surgical NSCLC patients

Not yet recruiting
4
78
 
None; None; None
Jiaozuo People's Hospital; Jiaozuo People's Hospital, Simcere Zaiming Pharmaceutical Co., Ltd.
Non small cell lung cancer
 
 
ChiCTR-TRC-11001703: Use MR functional imaging techniques to evaluate the efficacy of Endostar combined chemoradiotherapy

Completed
3
174
 
Concurrent chemotherapy, choose PP or NP, radiotherapy using conventional fractionation methods, PTV prescription dose 60-66Gy/6w, requires 95% PTV receiving 100% of the prescribed dose. ;Endostar started simultaneously with radiotherapy and chemotherapy ;Concurrent chemotherapy started 1 week before Endostar
Shandong Cancer Hospital; China International Medical Foundation（CIMF）, China International Medical Foundation (CIMF)
non-small cell lung cancer, NSCLC
 
 
NCT02001168: Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB

Active, not recruiting
3
392
RoW
Pemetrexed, Alimta, Docetaxel, Taxotere, rh-Endostatin, Endostar, Cis-platinum, Platinol
Xinjiang Medical University
Non-small Cell Lung Cancer
12/20
10/22
NCT04914598: A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions

Not yet recruiting
3
290
RoW
ENDOSTAR，cisplatin, Placebo , cisplatin
Jiangsu Simcere Pharmaceutical Co., Ltd.
Malignant Pleural Effusion
06/22
10/23
ECRP, ChiCTR-ONC-13003720: Clinical study of Endostar plus capecitabine combined with stereotactic radiotherapy in the treatment of advanced pancreatic cancer subjects open, single group phase II

Completed
2
100
 
Recombinant Human Endostatin Injection ;Capecitabine Tablet
Daping Hospital, Third Military Medical University; None, self-collected funds
Advanced pancreatic cancer
 
 
ChiCTR-OIC-17011304: The prospective, open-lable, single-arm, single-center phase II clinical study of endostar combined with AI in first-line treating patients with recurrent/metastatic soft tissue sarcoma

Recruiting
2
30
 
Endostar combined with AI
Breast, Bone and Soft tissue Oncology Department, affiliated Tumor Hospital, Guangxi Medical University; affiliated Tumor Hospital, Guangxi Medical University, self-financing
soft tissue sarcoma
 
 
NCT02350517: Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer

Completed
2
52
RoW
Paclitaxel+Nedaplatin+Endostar, Paclitaxl, Nedaplatin, Endostar, Recombinant Human Endostatin Injection
Yuhong Li
Esophageal Squamous Cell Carcinoma
12/19
12/22
ChiCTR-OIC-16009690: A open-lable, single-arm, single-center clinical trial to compare the efficacy and safety of Gemcitabine plus platinum with Endostar in the first-lined treatment of advanced triple-negative breast cancer

Not yet recruiting
2
20
 
Gemcitabine plus platinum with Endostar
The Affiliated Tumor Hospital of Guangxi Medical University; The Affiliated Tumor Hospital of Guangxi Medical University, Self-raised
advanced triple-negative breast cancer
 
 
NCT02636231: Endostar for Locally Recurrent Nasopharyngeal Carcinoma

Active, not recruiting
2
96
RoW
Endostatins, Endostar, IMRT
Sun Yat-sen University, JiangXi Province Tumor Hospital, The First Affiliated Hospital of Clinical Medicine of G.D.P.U., Second Affiliated Hospital of Nanchang University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, The Affiliated Ganzhou Hospital of Nanchang University, The First Hospital of Gannan Medical University
Nasopharyngeal Carcinoma
03/20
12/21
ChiCTR-OIN-17010698: Efficacy of recombinant human endostatin combined with TACE on hepatocellular carcinoma

Recruiting
2
164
 
Endostar
Fujian Provincial Cancer Hospital; Fujian Provincial Cancer Hospital, Fujian Key Laboratory of Translational Cancer Medicine
hepatocellular carcinoma
 
 
endorse, ChiCTR-OIC-17012754: An open-label, multicenter phase II trial of recombinant human endostatin, Endostar combined with cisplatin-based concurrent chemoradiation for patients with stage IIB-IIIB cervical cancer

Recruiting
2
60
 
recombinant human endostatin
Sichuan Cancer Hospital & Sichuan Cancer Center; Sichuan Cancer Hospital&Sichuan Cancer Center, None
Cervical Cancer
 
 
ChiCTR1800016259: A multicenter and randomized controlled clinical study on the treatment of malignant pleural effusion with Endostar and/or Nedaplatin

Recruiting
2
180
 
Endostar ;Nedaplatin ;Endostar and Nedaplatin
The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, self-finance
malignant pleural effusion
 
 
SLICER, NCT03989830: Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors

Recruiting
2
53
RoW
second-line chemotherapy, chemotherapy, Recombinant human endostatin, Endostar
Sun Yan, Peking University, Peking University Cancer Hospital & Institute
Head and Neck Neoplasms
06/21
06/22
ChiCTR1800018585: Exploratory, open and prospective clinical trial for continuous intravenous injection of Endostar (recombinant human endostain)combined with concurrent radiochemotherapy in the treatment of locally advanced cervical cancer

Recruiting
2
80
 
Endostar (recombinant human endostain)combined with concurrent radiochemotherapy
The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, Project funding
cervical cancer
 
 
ChiCTR2000032815: An explosive study for metastatic squamous lung cancer with fist-line treatment of recombinant human endostatin, PD-1 inhibitor and GP regimens

Not yet recruiting
2
20
 
Endostatin+IO+chemotherapy
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology; Tongji Hospital, Shandong Simcere-Medgenn Bio-Pharmaceutical Co., Ltd.; Xinda biopharmaceutical (Suzhou) Co., Ltd; Jiangsu Haosen Pharmaceutical Co., Ltd
Non-small cell lung cancer
 
 
MTAM, NCT04472806: Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Recruiting
2
31
RoW
Toripalimab, JS001, chemotherapy in combination with Endostar
Fudan University, Zhejiang Cancer Hospital, Fujian Cancer Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Mucosal Melanoma
06/22
06/23
ChiCTR2000030111: Phase II study for ENDOSTAR combined with concurrent chemoradiotherapy in the treatment of advanced esophageal cancer

Recruiting
2
40
 
radiation therapy + xeloda + platinum (cisplatin or nedaplatin) +ENDOSTAR
cancer hospital, chinese academy of medical sciences; Cancer Hospital, Chinese Academy of Medical Sciences, self-raised
esophageal cancer
 
 
NCT03932266: Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma

Not yet recruiting
2
73
NA
Endostar, Recombinant human endostatin injection, Cisplatin, Docetaxel, Intensity Modulated Radiation Therapy (IMRT)
Jiangsu Cancer Institute & Hospital
Nasopharyngeal Carcinoma
09/22
09/23
NCT05298020: Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

Not yet recruiting
2
20
RoW
Envafolimab, Immunotherapy, Endostar, endostatin, Nab paclitaxel, Chemotherapy, Gemcitabine
The Affiliated Hospital of Xuzhou Medical University
Advanced Pancreatic Cancer
12/22
04/23
NCT04303130: Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC

Recruiting
2
52
RoW
Camrelizumab, Endostar
Beijing Cancer Hospital, Peking University First Hospital, Peking University Third Hospital, Beijing Shijitan Hospital, Chinese PLA General Hospital, Peking Union Medical College Hospital, Peking University People's Hospital
Non-small Cell Lung Cancer
12/22
12/22
NCT04094909: Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC

Not yet recruiting
2
186
RoW
Rh-endostatin, Pembrolizumab, carboplatin, cisplatin, pemetrexed, [nab]-paclitaxel
Guangzhou Institute of Respiratory Disease
Staging IV NSCLC
12/22
03/23
ChiCTR2300079300: Application of camrelizumab combined with endostar in advanced non-small cell lung cancer

Completed
2
30
 
camrelizumab combined with endostar
Mudanjiang Cancer Hospital; Mudanjiang Cancer Hospital, self-funded
Lung cancer
 
 
NCT04659421: Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas

Completed
2
60
RoW
combined therapy with rh-ES and CV
Beijing Sanbo Brain Hospital
Low-grade Glioma, Pediatric Brain Tumor
07/23
07/23
ChESS, NCT03622827: Postoperative Concurrent Chemoradiotherapy Combined With Endostar for High-risk Early Stage Cervical Cancer

Recruiting
2
120
RoW
Chemoradiotherapy+ Endostar
Nanjing Medical University, Second Affiliated Hospital of Soochow University
Uterine Cervical Neoplasms
07/23
07/25
NCT04699214: Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment

Recruiting
2
210
RoW
Endostar (recombinant human endostatin injection), Chemotherapy AI
Yong Chen
Other Disorders of Soft Tissues
08/23
08/23
NCT05529355: Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

Not yet recruiting
2
45
NA
Envafolimab plus Endostar and S-1, Envafolimab combined with Recombinant Human Endostatin Injection/Tegafur,Gimeracil and Oteracil Porassium Capsules, Envafolimab plus Endostar, Envafolimab combined with Recombinant Human Endostatin Injection, Envafolimab plus S-1, Envafolimab combined with Tegafur,Gimeracil and Oteracil Porassium Capsules
Anhui Chest Hospital
Carcinoma, Non-Small-Cell Lung
09/23
09/23
FTANLCNDG, NCT05574998: First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial

Recruiting
2
100
RoW
Recombinant human endostatin (Endostar), Carboplatin, Cisplatin, Pemetrexed, Paclitaxel
Qianfoshan Hospital
Non-Small-Cell Lung Cancer
02/24
04/24
NCT06301828: Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors

Recruiting
2
16
RoW
Envafolimab Injection, KN035, Endostar, Recombinant Human Endostatin Injection
Nanjing First Hospital, Nanjing Medical University
Gastrointestinal Neoplasms
06/25
02/26
Endouble, NCT05203276: Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC

Recruiting
2
40
RoW
Envafolimab, EN WEI DA, Endostar, ENDO
The First People's Hospital of Lianyungang
Lung Neoplasms
05/24
06/24
NCT04447326: Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma

Not yet recruiting
2
106
NA
Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy, JS001, IC＋CCRT
First Affiliated Hospital of Guangxi Medical University, Shandong Cancer Hospital and Institute, Wuhan Union Hospital, China, The Affiliated Hospital Of Guizhou Medical University, Xiangya Hospital of Central South University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Fourth Affiliated Hospital of Guangxi Medical University, LiuZhou People's Hospital, Guilin Medical College, Affiliated Hospital of North Sichuan Medical College
Nasopharyngeal Carcinoma
06/24
06/26
ChiCTR2100046535: A real-world study of endostar combined with carrellizumab and chemotherapy for the first-line treatment of driving gene negative advanced NSCLC: an open, one arm, exploratory clinical study

Recruiting
2
40
 
Endostar and carrilizumab combined with chemotherapy were given
Nanping First Hospital Affiliated to Fujian Medical University; Nanping First Hospital Affiliated to Fujian Medical University, self-financed
Non small cell lung cancer
 
 
NCT05907512: Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

Recruiting
2
43
RoW
Endostar, Toripalimab
Fudan University
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
08/24
08/24
NCT06617936: Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Recruiting
2
35
RoW
neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy, surgery, Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar), Standard Treatment
Hua Zhang
Unresectable Non-small Cell Lung Cancer
08/25
09/27
NCT06055816: Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Recruiting
2
40
RoW
Endostar and Envafolimab
Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
09/24
06/28
ERR-NSCLC-01, NCT06618391: Local Injection and Systemic Therapy in the Treatment of NSCLC.

Not yet recruiting
2
84
NA
Envafolimab, PD-L1, Recombinant human endostatin, Endostar, recombinant human adenovirus type 5, OncorineR
Henan Cancer Hospital
Non-small Cell Lung Cancer
03/26
10/26
NCT05177237: Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma

Recruiting
2
30
RoW
Endostar, Re-human endostain
Jiangxi Provincial Cancer Hospital
Nasopharyngeal Carcinoma
12/24
12/25
FUMS-EDJS2024, NCT06965231: Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial

Recruiting
2
58
RoW
Toripalimab combined with Endostar
Fudan University, Fudan University Shanghai Cancer Center Minhang Branch Hospital, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 411 hospital
Melanoma of Skin, Acral Melanoma, Stage II Melanoma
12/28
03/29
ChiCTR2300079203: A Single-arm, Open-label Clinical Study of Enbrelizumab Combined with Endostar and Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Recruiting
2
25
 
Envafolimab combined with Endostar and concurrent chemoradiotherapy
Henan Provincial People's Hospital; Henan Provincial People's Hospital, Beijing Bethune Public Welfare Foundation
Locally advanced cervical cancer
 
 
IACE-OS, NCT06562673: Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma

Recruiting
1/2
10
RoW
intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar), intra-arterial treatment
Shanghai 6th People's Hospital
Osteosarcoma, Bone Cancer
09/25
10/25
ChiCTR-ONC-08000162: Combination chemotherapy with gemcitabine and cisplatin plus recombinant endostatin (endostar) and maintenance therapy with endostar in stage IIIB and IV NSCLC

Completed
1
200
 
administration of gemcitabine with cisplatin chemotherapy plus endostar
West China Hospital, Sichuan University; Simcere Pharmaceutical Company, Simcere Pharmaceutical Company
late stage of NSCLC
 
 
ChiCTR-TRC-08000115: Multicenter, double-blinding, randomized controlled, phase II clinical trial on combined chemotherapy of Endostar (Recombinant Human Endostatin) for untreated patients with advanced melanoma

Completed
1
140
 
Endostar combined with dacarbazine (add a drug that inhibits neovascularization to chemotherapy) ;Dacarbazine combined with placebo
Expert Committee for Melanoma of CSCO; Melanoma Experts Committee of Chinese Society of Clinical Oncology, Self-financing
Advanced melanoma
 
 
ChiCTR1800016085: TP-induction chemotherapy plus Intensity Modulated Radiaotherapy combined with anti-angiogenic targeted drugs (endostar) for recurrent nasopharyngeal carcinoma

Recruiting
1
30
 
TP-induction chemotherapy plus Intensity Modulated Radiaotherapy combined with anti-angiogenic targeted drugs (endostar)
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, China International Medical Foundation
Nasopharyngeal Carcinoma
 
 
NCT04942301: PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy

Not yet recruiting
1
24
RoW
Endostar, recombinant human endostatin injection, use the vein pump to pump drugs, vein pump, combination therapy
Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced or Metastatic NSCLC
12/21
10/22
ChiCTR-TNC-10000823: Phase II trial of etoposide/cisplatin with RH-endostain for patients with extensive-stage small-cell lung cancer

Completed
N/A
30
 
Cisplatin 25mg/m2 was administered intravenously over 30 to 60 minuteson on day 1-3; Etoposide 120mg/m2 was administered intravenously over 60 minutes on days 1-4; Endostar 15 mg was administered over 90 minutes by IV infusion on days 1-14; Repeated every 3 weeks for up to four cycles.
The First College Of Clinical Medical Science, China Three Gorges University ＆Yichang Central People's Hospital; The First College Of Clinical Medical Science, China Three Gorges University, self-funded
small-cell lung cancer
 
 
ChiCTR1800015862: Different administration of Endostar Combined with Paclitaxel and Carboplatin in the Treatment of Advanced Non Small Cell Lung Cancer

Recruiting
N/A
60
 
endostar continuous intravenous infusion by pumping ;endostar normal infusion group
Fujian Cancer Hospital; Fujian Cancer Hospital, No
Advanced Non Small Cell Lung Cancer
 
 
ChiCTR-IPR-17013479: Human recombinant endostatin (Endostar) combined with concurrent radiochemotherapy in patients with Inoperable stage III non-small cell lung cancer : a prospective, randomized controlled clinical study

Not yet recruiting
N/A
120
 
Endo combined with radiotherapy and chemotherapy on the 1st, 3rd, 5th and 7th week: Endostar: 7.5 mg / m2 / d × 7 days, continuous intravenous infusion, IMRT 6 to 7 weeks after the second week Strong radiotherapy): PTV 60-66GY / 30-33 times, concurrent chemotherapy: 2, 3,4,5,6,7,8 weeks, carboplatin AUC ;radiotherapy and chemotherapy
Affiliated hospital of Zunyi Medical University; Affiliated hospital of Zunyi Medical University, This work was supported by NSFC (Natural Science Foundation of China) , Start-Up Fund for Doctor of Zunyi Medical University and the Department of Science and Technology of Guizhou Province
Inoperable stage III non-small cell lung cancer
 
 
ChiCTR1900021786: Endostar combined with GP regimen chemotherapy in the treatment of local advanced or advanced squamous cell lung carcinoma

Recruiting
N/A
200
 
;
Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology; Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology, Self-financing
Squamous Cell Lung Carcinoma
 
 
ChiCTR2000035129: A Real-world Study of Endostar Combined with Chemotherapy and Chemoradiotherapy in the Treatment of Non-Small Cell Lung Cancer and Esophageal Cancer

Recruiting
N/A
3500
 
N/A
Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Hospital; Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Hospital, N/A
Non-small Cell Lung Cancer and Esophageal Cancer
 
 
ChiCTR1900021961: A multicenter study for efficacy and safety of endostar combined with chemotherapy for the treatment of relapsed or metastasis breast cancer

Not yet recruiting
N/A
50
 
endostar plus chemotherapy
Zhejiang Cancer Hospital; Zhejiang Cancer Hospital, Self-financing
Breast cancer
 
 
ChiCTR1900023714: Prospective clinical study for recombinant human endostatin combined with total central radiotherapy for recurrent medulloblastoma in children

Not yet recruiting
N/A
20
 
endostar plus radiotherapy
Army Characteristic Medical Center (Daping Hospital); Army Characteristic Medical Center (Daping Hospital), Self-financing
Medulloblastoma
 
 
ChiCTR1900023664: Study for PD-1 Inhibitor and Endostar in Previously Treated Advanced Non–Small-Cell Lung Cancer

Not yet recruiting
N/A
50
 
PD-1 Inhibitor and Endostar
The Fifth Affiliated Hospital, Sun Yat-sen University; The Fifth Affiliated Hospital, Sun Yat-sen University, none
lung cancer
 
 
ChiCTR1900026977: A real-world study for endostar and immunotherapy combined radiotherapy in the treatment of advanced lung cancer

Not yet recruiting
N/A
20
 
endostar and immunotherapy combined radiotherapy
Department of Oncology, the Second People's Hospital of Yibin; Department of Oncology, the Second People's Hospital of Yibin, no
advanced lung cancer
 
 
SBRTLCES, NCT04274270: SBRT With S1 Combined With Endostar in the Treatment of Lung Cancer

Not yet recruiting
N/A
60
RoW
Endostar, S1
Peking University Third Hospital, Mianyang Central Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Cancer Hospital, Peking University International Hospital, China-Japan Friendship Hospital, The fifth medical center of PLA general hospital, Second Hospital of Shanxi Medical University, Hiser Medical Center of Qingdao, Guangxi Ruikang Hospital, GEM flower hospital of Liaohe oil field, Tang-Du Hospital, Third Affiliated Hospital of Guizhou Medical University, Liuzhou Worker's Hospital, The Affiliated Hospital of Xuzhou Medical University, Dalian municipal central hospital affiliated of dalian medical university
Radiotherapy Side Effect
01/22
01/23
ChiCTR1900022095: A randomized controlled study for Endostar combined with PF regimen concurrent radiotherapy compare with PF regimen concurrent radiotherapy for Advanced esophageal cancer

Not yet recruiting
N/A
120
 
Endostar+chemoradiotherapy ;chemoradiotherapy
Red Cross Hosptical of Yulin; Red Cross Hosptical of Yulin, Self financing
esophageal cancer
 
 
R-helper, NCT04161352: Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC

Not yet recruiting
N/A
500
NA
Zhejiang Cancer Hospital
Unresectable Stage III NSCLC
06/22
12/23
ChiCTR2000033949: An exploratory clinical study of endostar combined with PD-1 antibody and Platinum-based dual drug regimen in the first-line treatment of advanced or metastatic non-small cell lung cancer

Not yet recruiting
N/A
96
 
endostar combined with PD-1 antibody and Platinum-based dual drug regimen
The Fifth Affiliated Hospital of Sun Yat-Sen University; The Fifth Affiliated Hospital of Sun Yat-Sen University, No financial support
Locally advanced or metastatic non-small cell lung cancer
 
 
ChiCTR2100051606: A single arm and a clinical pilot study of Envafolimab combined with Endostar and concurrent chemoradiotherapy in the treatment of unresectable locally advanced esophageal squamous cell carcinoma

Recruiting
N/A
105
 
Radiotherapy 50.4Gy/28次 ;Envafolimab; Endostar 75mg QW
Affiliated Cancer Hospital of Shandong First Medical University; Affiliated Cancer Hospital of Shandong First Medical University, No
Esophageal Squamous Cell Carcinoma
 
 
ChiCTR1900025638: Clinical study for recombinant human endostatin combined with chemoradiotherapy for glioma

Not yet recruiting
N/A
71
 
endostar plus chemoradiotherapy
Lanzhou University Second Hospital; Lanzhou University Second Hospital, Self-financing
glioma
 
 
ChiCTR1900027462: The real world of intravenous infusion of endostar combined with first-line immunotherapy for advanced or metastasis driven gene negative NSCLC

Not yet recruiting
N/A
224
 
Endostar, PD-1/PD-L1 and conventional chemotherapy ;Endostar combined with chemotherapy
Guangxi Medical University Affiliated Tumor Hospital; Guangxi Medical University Affiliated Tumor Hospital, nothing
NSCLC
 
 
ChiCTR1900022096: A randomized controlled study for Endostar and Hyperthermia Combined with chemoradiotherapy for locally advanced esophageal cancer

Not yet recruiting
N/A
400
 
chemoradiotherapy ;Endostar Combined with chemoradiotherapy ;Hyperthermia Combined with chemoradiotherapy ;Endostar and hyperthermia Combined with chemoradiotherapy
The Second Affilicated Hosptical of Guangxi Medical University; The Second Affilicated Hosptical of Guangxi Medical University, Self financing
esophageal cancer
 
 
ChiCTR2100045038: Short-Term Efficacy of Local Iodine Pleurodesis Versus Intrapleural Perfusion of Recombinant Human Endostatin Combined with Cisplatin in the Treatment of Non-small Cell Lung Cancer Complicated With Malignant Pleural Effusion: a Randomized Clinical Study

Recruiting
N/A
152
 
Intrapleural perfusion of endostar combined with cisplatin ;Iodophor was injected into the chest
Peking University First Hospital; Peking University First Hospital, None
Malignant pleural effusion from non-small cell lung cancer
 
 
NCT05879796: Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer

Not yet recruiting
N/A
30
NA
cis-platinum, Cisplatin, radiation, External beam radiotherapy, Brachytherapy, Envafolimab Injection, KN035, Recombinant Human Endostatin Injection, endostar
Peking University Third Hospital
Cervical Cancer
05/24
05/26
ChiCTR2100054796: An exploratory single-arm clinical study of β -glucan combined with Envafolimab and Endostar as second-line treatment for advanced NSCLC after PD-1 inhibitor failure

Not yet recruiting
N/A
30
 
Beta-glucan in combination with Nvorimab and Endostat
Changzhou Second People's Hospital; Changzhou Second People's Hospital, Self-financed
Non-small cell lung cancer
 
 
ChiCTR2400088085: Efficacy and safety of intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) combined with systematic chemotherapy in osteosarcoma

Not yet recruiting
N/A
10
 
Intravenous (2-4 cycles): Methotrexate 10g/m2; Doxorubicin 60-75mg/m2 Arteries (2-4 cycles): Recombinant endostatin 150mg infused for 6 hours; Cisplatin 120mg/m2 infusion for 6 hours
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, none
osteosarcoma
 
 
ChiCTR2500100417: Efficacy and safety analysis of Endostar in cross-line therapy in patients with advanced non-small cell lung cancer

Recruiting
N/A
290
 
None. Continue Endostar antiangiogenic therapy after the first progression; None. Endostar antiangiogenic therapy is no longer used after the first progression
The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university, Beijing Life Oasis public Service Center
Non-small cell lung cancer
 
 
ChiCTR2200062942: A single-arm, exploratory trial of Envafolimab in combination with endostar and concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma

Not yet recruiting
N/A
50
 
Envafolimab in combination with endostar and concurrent chemoradiotherapy
First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Zhengzhou University, Jiangsu Simcere Pharmaceutical Co. , Ltd.
Esophageal squamous cell carcinoma
 
 
suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
SCORES, NCT04908787: A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Active, not recruiting
3
421
RoW
BD0801, Paclitaxel, Placebo, Topotecan, doxorubicin liposome
Jiangsu Simcere Pharmaceutical Co., Ltd., Shanghai Xianxiang Medical Technology Co., Ltd.
Ovarian Cancer
12/23
12/24
NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

Terminated
2
86
RoW
Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine
Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Solid Tumor
07/23
07/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Iremod (iguratimod) / Simcere
NCT04981145: The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome

Recruiting
4
78
RoW
Iguratimod Tablets, Hydroxychloroquine Sulfate Tablets
Second Affiliated Hospital, School of Medicine, Zhejiang University
Primary Sjögren's Syndrome
12/24
07/25
NCT05803135: Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis

Not yet recruiting
4
138
NA
Iguratimod combined with Tofacitinib;, Placebo of Iguratimod combined with Tofacitinib
Nanfang Hospital of Southern Medical University, Jiangsu Simcere Pharmaceutical Co., Ltd.
Rheumatoid Arthritis
01/25
12/25
ChiCTR2000029112: A Multi-center, Randomized, Double-blind, Placebo-controlled Trial for the Efficacy and Safety of Iguratimod in Combination With Celecoxib in the Treatment of Ankylosing Spondylitis (AS) or Axial Spondyloarthritis (axSpA)

Recruiting
3
240
 
lguratimod plus NSAID ;placebo plus NSAID
Ruijin Hospital; Ruijin Hospital, Jiangsu Simcere Pharmaceuticals
Ankylosing Spondylitis /Axial Spondyloarthritis
 
 
NCT04830644: A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.

Recruiting
2
144
RoW
Iguratimod, Placebo
Jiangsu Simcere Pharmaceutical Co., Ltd.
Primary Sjögren Syndrome
04/22
06/22
NCT05281068: The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Recruiting
2
120
RoW
Iguratimod, Iremod, Danazol
Peking University People's Hospital, Beijing Hospital, China-Japan Friendship Hospital, Beijing Friendship Hospital, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Chongqing Medical University, Shanxi Bethune hospital, Shanxi, China
ITP, Immune Thrombocytopenia
09/23
12/23
ChiCTR1900021345: Effect of Iguratimod on Primary Sjogren's Syndrome

Recruiting
N/A
60
 
Hydrochloroquine ;Iguratimod
Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, China International Medical Exchange Foundation Simcere Clinical Research Project Fund
Primary Sjogren's Syndrome
 
 
Endostar (recombinant human endostatin) / Simcere
ChiCTR-TRC-10001187: Prospective, open, multicentre clinical trial (phase II) of Endostar(recombinant human endostatin) on combined radiotherapy and chemotherapy for esophageal cancer

Completed
4
60
 
Endostar: 7.5mg/m2, D1-D14, D21-35; for 2 cycles; Paclitaxel Injection: 175mg/m2, D1; DDP: 75-90mg/m2, D1; E=6MV, GTV-P: 60-66Gy/30-33every time/6~7w (2Gy-2.1/every time), CTVN-P: 51Gy/30 (1.7Gy/every time) ;Paclitaxel Injection: 175mg/m2, D1; DDP: 75-90mg/m2, D1; E=6MV, GTV-P: 60-66Gy/30-33every time/6-7w (2Gy-2.1/every time), CTVN-P: 51Gy/30 (1.7Gy/every time)
Fujian Provincial Tumor Hospital; Jiangsu Simcere pharmaceutical Co.Ltd, Jiangsu Simcere pharmaceutical Co.Ltd
ⅡB, III, IV esophageal cancer
 
 
ChiCTR-TRC-11001424: Search of TEC ally Endostar used in preoperative chemotherapy in breast cancer stage III

Completed
4
160
 
TEC ;TEC+ Endostar
Hebei Medical University Fourth Hospital; Hebei Medical University Fourth Hospital, self-funding
breast cancer
 
 
ChiCTR-TRC-12001891: randomized control trial of Endostar in deferent time combined with DP regime for IIIB-IV stage NSCLC

Completed
4
150
 
Endostar combined with DP regime in three different times
Nantong Tumor Hospital; Jiangsu Xiansheng Pharmaceutical Co., Ltd, Simcere Company
None Small Cell Lung Cancer
 
 
ChiCTR-ONRC-11001598: Phase II trial of Endostar combined with CHOPT for T cell lymphoma

Completed
4
30
 
Endostar combined with CHOPT regime
Tianjin Medical University Cancer Institute and Hospital; Jiangsu Xiansheng Pharmaceutical Co., Ltd, Simcere Company
T cell lymphoma
 
 
ChiCTR-TNRC-10000944: Clinical research on the theraputic effect of recombined human endostatin with interventional therapy for hepatic metastatic tumor from gastrointestinal tract

Completed
4
60
 
treated with only interventional therapy ;treated with rh-endostatin and interventional ther
NanJing Jinling Hospital; Simcere Pharmaceutical Industries Co., Ltd, simcere Pharmaceutical Industries Co., Ltd
hepatic metastatic tumor
 
 
ChiCTR-TRC-12002363: Clinical study of recombinant human endostatin in deferent time combined with paclitaxel and cisplatin in treatment of advanced none-small cell lung cancer

Completed
4
90
 
human endostatin 7.5mg/m2 + Cisplatin 175mg/m2 +TP 80mg/m2 iv in day 1 and three weeks repeat and total two cycles ;human endostatin 7.5mg/m2 for 14 days +TP 80mg/m2 iv in day 1 and + Cisplatin 175mg/m2 in day 5 five weeks repeat and total two cycles ;TP 80mg/m2 iv in day 1 and + Cisplatin 175mg/m2 in day 5 five weeks repeat and total two cycles
Sichuan Province Luzhou Medical College affiliated Hospital; Simcere Pharmaceutical Company, Simcere Pharmaceutical Company
None Small Cell Lung Cancer
 
 
ChiCTR-IPR-17011666: Effect of recombinant human endostatin on the clinical treatment of malignant cavity effusion

Completed
4
84
 
only given Endostar ;Endostar combined with cisplatin ;only treated with cisplatin
Medical Department of Dalian University; Affiliated Zhongshan Hospital of Dalian University, Wu Jieping Medical Foundation Clinical Research Special Project Fund
malignant cavity effusion
 
 
ChiCTR-ONRC-14004210: Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Completed
4
20
 
drug therapy
Beijing Tiantan Hospital Affiliated to Capital Medical University; Beijing Tiantan Hospital Affiliated to Capital Medical University, Shandong Simcere-Medgenn Bio-pharmaceutical Co.,Ltd.
Neurofibromatosis type 2
 
 
ChiCTR-IPR-16008803: The randomized controlled study of intrathoracic application of recombinant human endostatin single or combined with cisplatin for the treatment of malignant pleural effusion

Not yet recruiting
4
60
 
endostar monotherapy ;endostar combined cisplatin ;Cisplatin monotherapy
Chongqing Cancer Hospital; Chongqing cancer hospital, Chongqing cancer hospital
lung cancer
 
 
ChiCTR-IPR-16009926: Recombinant human endostatin (Endostar) continuous pump infusion combined with concurrent radiochemotherapy in patients with esophageal squamous cell cancer: a prospective, randomized controlled clinical study

Not yet recruiting
4
120
 
Endostar:15mg/d, continuous pump infusion within 1 week before radiotherapy, and then concurrent with radiothetapy (continuous pump infusion for 5 days, and then rest for 2 days), total 6 weeks. Radiotherapy: 3D-CRT/IMRT/IGRT; Involved field irradiation(IFI), GTV for esophageal primary tumor, GTVnd for metastatic lymph nodes,&; Radiotherapy: 3D-CRT/IMRT/IGRT; Involved field irradiation(IFI), GTV for esophageal primary tumor, GTVnd for metastatic lymph nodes, CTV as 3cm upward and 4cm downward of GTV; 95% prescription dose: PGTV 60-66Gy/30-33f, PTV 46-50Gy/23-25f.Chemotherapy: Docetaxel 60mg/m2, d1; Cisplatin 25mg/m2,d1-3; 21-28d/cycle, 2-4cycles.
Gansu Provincial Cancer Hospital; Gansu Provincial Cancer Hospital, Seif-financing
Esophageal cancer
 
 
ChiCTR-IPR-17010441: Human Recombinant Endostatin Injection Durative Transfusion Combined With Chemotherapy in The First-line Treatment of Advanced Lung Squamous Carcinoma

Recruiting
4
220
 
human recombinant human endostatin(endostar) injection combined with chemotheapy ;chemotheapy
The First Affiliated Hospital of Wannan Medical College; The First Affiliated Hospital of Wannan Medical College, self-financing
Squamous Cell Lung Cancer
 
 
ChiCTR2000040892: Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in treating patients with locally advanced cervical cancer

Completed
4
116
 
Cisplatin: 40 mg/m2 for 5 weeks; IMRT: PTV1 50-54 Gy; PTV2 45-48.6 Gy; PTV3 45-48.6 Gy; HDR brachtherapy: 24 Gy in 4 fractions ;Endostar 7.5 mg/m2/d from D1 to D14 for 2 cycles, starting on the first day of IMRT; Cisplatin: 40 mg/m2/w for 5 weeks; IMRT: PTV1 50-54 Gy; PTV2 45-48.6 Gy; PTV3 45-48.6 Gy; HDR brachtherapy: 24 Gy in 4 fractions
People's Hospital of Guangxi Zhuang Autonomous Region; People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Medical and Health Care Appropriate Technology Development and Promotion Program
Cervical cancer
 
 
ChiCTR-IPR-17011374: Human recombinant endostatin (Endostar) combined with concurrent radiochemotherapy in patients with cervical squamous cell cancer: a prospective, randomized controlled clinical study

Recruiting
4
100
 
Human recombinant endostatin (Endostar) combined with concurrent radiochemotherapy ;concurrent radiochemotherapy
The Cancer Hospital of Gansu Province; The Cancer Hospital of Gansu Province, Seif-financing
cervical cancer
 
 
ChiCTR1900021279: A clinical study for Endostar combined with TP regimen concurrent radiotherapy for esophageal cancer: a randomized controlled trial

Recruiting
4
80
 
Endostar+chemoradiotherapy ;Chemoradiotherapy
The Second Affiliated Hospital of Xi'an Jiaotong University; The Second Affiliated Hospital of Xi'an Jiaotong University, Self financing
Esophageal cancer
 
 
ChiCTR2000033802: Clinical trial of different administration of endostar in the treatment of advanced non-small cell lung cancer with malignant pleural effusion

Not yet recruiting
4
60
 
Intravenous drip endostar; perfusion endostar into pleural
Xinjiang Medical University Affiliated Oncology Hospital; Xinjiang Medical University Affiliated Oncology Hospital, No
Non small cell lung cancer
 
 
ChiCTR1800014879: Study on antiangiogenic transformation medicine of advanced colorectal cancer based on APE1 expression

Not yet recruiting
4
116
 
Endostar combined with FOLFOX ;FOLFOX
Daping Hospital, Chongqing; Daping Hospital，Chongqing, Project funding
Colorectal cancer
 
 
RELIEF, NCT04613284: Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC

Not yet recruiting
4
97
NA
Recombinant human endostatin (Endostar), Durvalumab, Thoracic irradiation of 50 Gy with 3DCRT or IMRT
Shanghai Chest Hospital, Wuhan University
Lung Cancer
02/22
08/23
ChiCTR1900024622: A multicenter, randomized controlled trial for ENDOSTAR intravenous infusion combined with AP/GP versus AP/GP for the first-line treatment of stage IIIB-IV-driven gene-negative lung adenocarcinoma and lung squamous cell carcinoma

Not yet recruiting
4
346
 
ENDOSTAR & AP ;AP ;ENDOSTAR & GP ;GP
Zhujiang Hospital of Southern Medical University; Zhujiang Hospital of Southern Medical University, Zhujiang Hospital of Southern Medical University
Lung cancer
 
 
ChiCTR2100053353: A trial of three-day continuous Osmotic Pump of endostar combined with platinum-based chemotherapy plus Sindilizumab? for treatment? advanced non-small-cell lung cancer

Not yet recruiting
4
20
 
three-day continuous Osmotic Pump of endostar combined with platinum-based chemotherapy plus Sindilizumab
Zigong First People's Hospital, Sichuan Province; Zigong First People's Hospital, Sichuan Province, Zigong First People's Hospital, Sichuan Province
lung caner
 
 
ChiCTR2100050095: A single-arm, multi-center, prospective clinical study of recombinant human endostatin injection combined with afatinib maleate tablets and Siggio capsules in the second-line treatment of advanced squamous cell carcinoma of the lung

Not yet recruiting
4
30
 
recombinant human endostatin injection combined with afatinib dimaleate tablets and tegafur, gimeracil and oteracil potassium capsules
The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, China International Medical Exchange Foundation - Simcere Clinical Research Special Fund
advanced lung squamous cell carcinoma
 
 
ChiCTR2200064150: Study of continuous intravenous infusion of rh-endostatin for three days in the combination chemotherapy of advanced NSCLC with negative driver gene mutation

Not yet recruiting
4
68
 
continuous intravenous infusion of rh-endostatin for three days in the combination chemotherapy
Shanghai General Hospital; Shanghai General Hospital, Shandong Simcere Bio-Pharmaceutical Co., Ltd.
Non-small cell lung cancer
 
 
ChiCTR2200060332: Concurrent chemoradiotherapy with or without recombinant human endostatin (Endo) consolidation with envafolimab in patients with stage III unresectable non-small cell lung cancer (NSCLC)

Not yet recruiting
4
72
 
The dose of Endostar is 7.5 mg/m2, continuous intravenous infusion 5 days a week, starting 5 days before radiotherapy, one cycle every 2 weeks, a total of 4 cycles. Synchronous EP program for 3 cycles. Consolidation therapy with enverolimab was started 14 days to 30 days after the end of radiotherap ;3 cycles of radiotherapy synchronous EP program. 14 days to 30 days after the end of radiotherapy, Envolimumab consolidation therapy was started, 400 mg each time, 28 days/time, until disease progression or intolerance, and the longest treatment time was 1 year.
Jiamusi Cancer Hospital; Jiamusi Cancer Hospital, China International Medical Foundation
Stage III unresectable non-small cell lung cancer
 
 
ChiCTR2100042088: Recombinant Human Endostatin Combined With Platinum-Containing Dual Drug for the First-Line Treatment of Driver Gene-Negative Advanced Non-Small Cell Lung Cancer: a Multicenter, Single-Arm Trial

Recruiting
4
100
 
Endostar (210mg, durative transfused for 120 hours) was administered every three weeks beginning on the first day of each treatment cycle. Carboplatin (AUC 5-6) or cisplatin (75mg/m2)+pemetrexed (500 mg/m2) Q3W with 4 cycles, followed by Endostar+ pemetrexed at the end of 4 cycles until disease progression or i ;Endostar (210mg, durative transfused for 120 hours) was administered every three weeks beginning on the first day of each treatment cycle. Carboplatin(AUC 5-6) or cisplatin (75 mg/m2)+Paclitaxel (175 mg/m2) Q3W with 4 cycles, followed by Endostar at the end of 4 cycles until disease progression or intolerable t
The First Affiliated Hospital of Shandong First Medical University; The First Affiliated Hospital of Shandong First Medical University, Self-financing
Advanced Non-small Cell Lung Cancer
 
 
ChiCTR2200064322: Study on the efficacy and safety of recombinant human endostatin combined with PD1 inhibitor and chemotherapy in the treatment of pancreatic cancer

Not yet recruiting
4
60
 
Endostar + Camrelizumab + Chemotherapy ;Chemotherapy
The Affiliated People's Hospital of Jiangsu University ; The Affiliated People's Hospital of Jiangsu University, China International Medical Exchange Foundation Xiansheng clinical research special fund
Pancreatic cancer
 
 
ChiCTR2300070009: A single-arm, exploratory clinical study of 3-day continuous intravenous pump of endostatin (endostar) combined with chemotherapy and immune checkpoint inhibitor in the treatment of advanced lung squamous cell carcinom

Not yet recruiting
4
30
 
3-day continuous intravenous pump of endostatin (endostar) combined with chemotherapy and immune checkpoint inhibiton
Yancheng First People's Hospital; Yancheng First People's Hospital, scientific research task
advanced lung squamous cell carcinom
 
 
NCT05782764: A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom

Recruiting
4
30
RoW
To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV)., Endostar combined with immune checkpoint inhibitor and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV)
Xuzhou Medical University
Lung Squamous Cell Carcinoma
05/25
05/25
ChiCTR2400085777: A multicenter real-world study on the efficacy and safety of recombinant human endostatin combined with chemotherapy and PD-1/PD-L1 first-line treatment in non-surgical NSCLC patients

Not yet recruiting
4
78
 
None; None; None
Jiaozuo People's Hospital; Jiaozuo People's Hospital, Simcere Zaiming Pharmaceutical Co., Ltd.
Non small cell lung cancer
 
 
ChiCTR-TRC-11001703: Use MR functional imaging techniques to evaluate the efficacy of Endostar combined chemoradiotherapy

Completed
3
174
 
Concurrent chemotherapy, choose PP or NP, radiotherapy using conventional fractionation methods, PTV prescription dose 60-66Gy/6w, requires 95% PTV receiving 100% of the prescribed dose. ;Endostar started simultaneously with radiotherapy and chemotherapy ;Concurrent chemotherapy started 1 week before Endostar
Shandong Cancer Hospital; China International Medical Foundation（CIMF）, China International Medical Foundation (CIMF)
non-small cell lung cancer, NSCLC
 
 
NCT02001168: Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB

Active, not recruiting
3
392
RoW
Pemetrexed, Alimta, Docetaxel, Taxotere, rh-Endostatin, Endostar, Cis-platinum, Platinol
Xinjiang Medical University
Non-small Cell Lung Cancer
12/20
10/22
NCT04914598: A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions

Not yet recruiting
3
290
RoW
ENDOSTAR，cisplatin, Placebo , cisplatin
Jiangsu Simcere Pharmaceutical Co., Ltd.
Malignant Pleural Effusion
06/22
10/23
ECRP, ChiCTR-ONC-13003720: Clinical study of Endostar plus capecitabine combined with stereotactic radiotherapy in the treatment of advanced pancreatic cancer subjects open, single group phase II

Completed
2
100
 
Recombinant Human Endostatin Injection ;Capecitabine Tablet
Daping Hospital, Third Military Medical University; None, self-collected funds
Advanced pancreatic cancer
 
 
ChiCTR-OIC-17011304: The prospective, open-lable, single-arm, single-center phase II clinical study of endostar combined with AI in first-line treating patients with recurrent/metastatic soft tissue sarcoma

Recruiting
2
30
 
Endostar combined with AI
Breast, Bone and Soft tissue Oncology Department, affiliated Tumor Hospital, Guangxi Medical University; affiliated Tumor Hospital, Guangxi Medical University, self-financing
soft tissue sarcoma
 
 
NCT02350517: Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer

Completed
2
52
RoW
Paclitaxel+Nedaplatin+Endostar, Paclitaxl, Nedaplatin, Endostar, Recombinant Human Endostatin Injection
Yuhong Li
Esophageal Squamous Cell Carcinoma
12/19
12/22
ChiCTR-OIC-16009690: A open-lable, single-arm, single-center clinical trial to compare the efficacy and safety of Gemcitabine plus platinum with Endostar in the first-lined treatment of advanced triple-negative breast cancer

Not yet recruiting
2
20
 
Gemcitabine plus platinum with Endostar
The Affiliated Tumor Hospital of Guangxi Medical University; The Affiliated Tumor Hospital of Guangxi Medical University, Self-raised
advanced triple-negative breast cancer
 
 
NCT02636231: Endostar for Locally Recurrent Nasopharyngeal Carcinoma

Active, not recruiting
2
96
RoW
Endostatins, Endostar, IMRT
Sun Yat-sen University, JiangXi Province Tumor Hospital, The First Affiliated Hospital of Clinical Medicine of G.D.P.U., Second Affiliated Hospital of Nanchang University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, The Affiliated Ganzhou Hospital of Nanchang University, The First Hospital of Gannan Medical University
Nasopharyngeal Carcinoma
03/20
12/21
ChiCTR-OIN-17010698: Efficacy of recombinant human endostatin combined with TACE on hepatocellular carcinoma

Recruiting
2
164
 
Endostar
Fujian Provincial Cancer Hospital; Fujian Provincial Cancer Hospital, Fujian Key Laboratory of Translational Cancer Medicine
hepatocellular carcinoma
 
 
endorse, ChiCTR-OIC-17012754: An open-label, multicenter phase II trial of recombinant human endostatin, Endostar combined with cisplatin-based concurrent chemoradiation for patients with stage IIB-IIIB cervical cancer

Recruiting
2
60
 
recombinant human endostatin
Sichuan Cancer Hospital & Sichuan Cancer Center; Sichuan Cancer Hospital&Sichuan Cancer Center, None
Cervical Cancer
 
 
ChiCTR1800016259: A multicenter and randomized controlled clinical study on the treatment of malignant pleural effusion with Endostar and/or Nedaplatin

Recruiting
2
180
 
Endostar ;Nedaplatin ;Endostar and Nedaplatin
The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, self-finance
malignant pleural effusion
 
 
SLICER, NCT03989830: Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors

Recruiting
2
53
RoW
second-line chemotherapy, chemotherapy, Recombinant human endostatin, Endostar
Sun Yan, Peking University, Peking University Cancer Hospital & Institute
Head and Neck Neoplasms
06/21
06/22
ChiCTR1800018585: Exploratory, open and prospective clinical trial for continuous intravenous injection of Endostar (recombinant human endostain)combined with concurrent radiochemotherapy in the treatment of locally advanced cervical cancer

Recruiting
2
80
 
Endostar (recombinant human endostain)combined with concurrent radiochemotherapy
The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, Project funding
cervical cancer
 
 
ChiCTR2000032815: An explosive study for metastatic squamous lung cancer with fist-line treatment of recombinant human endostatin, PD-1 inhibitor and GP regimens

Not yet recruiting
2
20
 
Endostatin+IO+chemotherapy
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology; Tongji Hospital, Shandong Simcere-Medgenn Bio-Pharmaceutical Co., Ltd.; Xinda biopharmaceutical (Suzhou) Co., Ltd; Jiangsu Haosen Pharmaceutical Co., Ltd
Non-small cell lung cancer
 
 
MTAM, NCT04472806: Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Recruiting
2
31
RoW
Toripalimab, JS001, chemotherapy in combination with Endostar
Fudan University, Zhejiang Cancer Hospital, Fujian Cancer Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Mucosal Melanoma
06/22
06/23
ChiCTR2000030111: Phase II study for ENDOSTAR combined with concurrent chemoradiotherapy in the treatment of advanced esophageal cancer

Recruiting
2
40
 
radiation therapy + xeloda + platinum (cisplatin or nedaplatin) +ENDOSTAR
cancer hospital, chinese academy of medical sciences; Cancer Hospital, Chinese Academy of Medical Sciences, self-raised
esophageal cancer
 
 
NCT03932266: Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma

Not yet recruiting
2
73
NA
Endostar, Recombinant human endostatin injection, Cisplatin, Docetaxel, Intensity Modulated Radiation Therapy (IMRT)
Jiangsu Cancer Institute & Hospital
Nasopharyngeal Carcinoma
09/22
09/23
NCT05298020: Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

Not yet recruiting
2
20
RoW
Envafolimab, Immunotherapy, Endostar, endostatin, Nab paclitaxel, Chemotherapy, Gemcitabine
The Affiliated Hospital of Xuzhou Medical University
Advanced Pancreatic Cancer
12/22
04/23
NCT04303130: Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC

Recruiting
2
52
RoW
Camrelizumab, Endostar
Beijing Cancer Hospital, Peking University First Hospital, Peking University Third Hospital, Beijing Shijitan Hospital, Chinese PLA General Hospital, Peking Union Medical College Hospital, Peking University People's Hospital
Non-small Cell Lung Cancer
12/22
12/22
NCT04094909: Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC

Not yet recruiting
2
186
RoW
Rh-endostatin, Pembrolizumab, carboplatin, cisplatin, pemetrexed, [nab]-paclitaxel
Guangzhou Institute of Respiratory Disease
Staging IV NSCLC
12/22
03/23
ChiCTR2300079300: Application of camrelizumab combined with endostar in advanced non-small cell lung cancer

Completed
2
30
 
camrelizumab combined with endostar
Mudanjiang Cancer Hospital; Mudanjiang Cancer Hospital, self-funded
Lung cancer
 
 
NCT04659421: Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas

Completed
2
60
RoW
combined therapy with rh-ES and CV
Beijing Sanbo Brain Hospital
Low-grade Glioma, Pediatric Brain Tumor
07/23
07/23
ChESS, NCT03622827: Postoperative Concurrent Chemoradiotherapy Combined With Endostar for High-risk Early Stage Cervical Cancer

Recruiting
2
120
RoW
Chemoradiotherapy+ Endostar
Nanjing Medical University, Second Affiliated Hospital of Soochow University
Uterine Cervical Neoplasms
07/23
07/25
NCT04699214: Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment

Recruiting
2
210
RoW
Endostar (recombinant human endostatin injection), Chemotherapy AI
Yong Chen
Other Disorders of Soft Tissues
08/23
08/23
NCT05529355: Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

Not yet recruiting
2
45
NA
Envafolimab plus Endostar and S-1, Envafolimab combined with Recombinant Human Endostatin Injection/Tegafur,Gimeracil and Oteracil Porassium Capsules, Envafolimab plus Endostar, Envafolimab combined with Recombinant Human Endostatin Injection, Envafolimab plus S-1, Envafolimab combined with Tegafur,Gimeracil and Oteracil Porassium Capsules
Anhui Chest Hospital
Carcinoma, Non-Small-Cell Lung
09/23
09/23
FTANLCNDG, NCT05574998: First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial

Recruiting
2
100
RoW
Recombinant human endostatin (Endostar), Carboplatin, Cisplatin, Pemetrexed, Paclitaxel
Qianfoshan Hospital
Non-Small-Cell Lung Cancer
02/24
04/24
NCT06301828: Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors

Recruiting
2
16
RoW
Envafolimab Injection, KN035, Endostar, Recombinant Human Endostatin Injection
Nanjing First Hospital, Nanjing Medical University
Gastrointestinal Neoplasms
06/25
02/26
Endouble, NCT05203276: Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC

Recruiting
2
40
RoW
Envafolimab, EN WEI DA, Endostar, ENDO
The First People's Hospital of Lianyungang
Lung Neoplasms
05/24
06/24
NCT04447326: Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma

Not yet recruiting
2
106
NA
Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy, JS001, IC＋CCRT
First Affiliated Hospital of Guangxi Medical University, Shandong Cancer Hospital and Institute, Wuhan Union Hospital, China, The Affiliated Hospital Of Guizhou Medical University, Xiangya Hospital of Central South University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Fourth Affiliated Hospital of Guangxi Medical University, LiuZhou People's Hospital, Guilin Medical College, Affiliated Hospital of North Sichuan Medical College
Nasopharyngeal Carcinoma
06/24
06/26
ChiCTR2100046535: A real-world study of endostar combined with carrellizumab and chemotherapy for the first-line treatment of driving gene negative advanced NSCLC: an open, one arm, exploratory clinical study

Recruiting
2
40
 
Endostar and carrilizumab combined with chemotherapy were given
Nanping First Hospital Affiliated to Fujian Medical University; Nanping First Hospital Affiliated to Fujian Medical University, self-financed
Non small cell lung cancer
 
 
NCT05907512: Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

Recruiting
2
43
RoW
Endostar, Toripalimab
Fudan University
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
08/24
08/24
NCT06617936: Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Recruiting
2
35
RoW
neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy, surgery, Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar), Standard Treatment
Hua Zhang
Unresectable Non-small Cell Lung Cancer
08/25
09/27
NCT06055816: Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Recruiting
2
40
RoW
Endostar and Envafolimab
Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
09/24
06/28
ERR-NSCLC-01, NCT06618391: Local Injection and Systemic Therapy in the Treatment of NSCLC.

Not yet recruiting
2
84
NA
Envafolimab, PD-L1, Recombinant human endostatin, Endostar, recombinant human adenovirus type 5, OncorineR
Henan Cancer Hospital
Non-small Cell Lung Cancer
03/26
10/26
NCT05177237: Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma

Recruiting
2
30
RoW
Endostar, Re-human endostain
Jiangxi Provincial Cancer Hospital
Nasopharyngeal Carcinoma
12/24
12/25
FUMS-EDJS2024, NCT06965231: Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial

Recruiting
2
58
RoW
Toripalimab combined with Endostar
Fudan University, Fudan University Shanghai Cancer Center Minhang Branch Hospital, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 411 hospital
Melanoma of Skin, Acral Melanoma, Stage II Melanoma
12/28
03/29
ChiCTR2300079203: A Single-arm, Open-label Clinical Study of Enbrelizumab Combined with Endostar and Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Recruiting
2
25
 
Envafolimab combined with Endostar and concurrent chemoradiotherapy
Henan Provincial People's Hospital; Henan Provincial People's Hospital, Beijing Bethune Public Welfare Foundation
Locally advanced cervical cancer
 
 
IACE-OS, NCT06562673: Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma

Recruiting
1/2
10
RoW
intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar), intra-arterial treatment
Shanghai 6th People's Hospital
Osteosarcoma, Bone Cancer
09/25
10/25
ChiCTR-ONC-08000162: Combination chemotherapy with gemcitabine and cisplatin plus recombinant endostatin (endostar) and maintenance therapy with endostar in stage IIIB and IV NSCLC

Completed
1
200
 
administration of gemcitabine with cisplatin chemotherapy plus endostar
West China Hospital, Sichuan University; Simcere Pharmaceutical Company, Simcere Pharmaceutical Company
late stage of NSCLC
 
 
ChiCTR-TRC-08000115: Multicenter, double-blinding, randomized controlled, phase II clinical trial on combined chemotherapy of Endostar (Recombinant Human Endostatin) for untreated patients with advanced melanoma

Completed
1
140
 
Endostar combined with dacarbazine (add a drug that inhibits neovascularization to chemotherapy) ;Dacarbazine combined with placebo
Expert Committee for Melanoma of CSCO; Melanoma Experts Committee of Chinese Society of Clinical Oncology, Self-financing
Advanced melanoma
 
 
ChiCTR1800016085: TP-induction chemotherapy plus Intensity Modulated Radiaotherapy combined with anti-angiogenic targeted drugs (endostar) for recurrent nasopharyngeal carcinoma

Recruiting
1
30
 
TP-induction chemotherapy plus Intensity Modulated Radiaotherapy combined with anti-angiogenic targeted drugs (endostar)
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, China International Medical Foundation
Nasopharyngeal Carcinoma
 
 
NCT04942301: PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy

Not yet recruiting
1
24
RoW
Endostar, recombinant human endostatin injection, use the vein pump to pump drugs, vein pump, combination therapy
Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced or Metastatic NSCLC
12/21
10/22
ChiCTR-TNC-10000823: Phase II trial of etoposide/cisplatin with RH-endostain for patients with extensive-stage small-cell lung cancer

Completed
N/A
30
 
Cisplatin 25mg/m2 was administered intravenously over 30 to 60 minuteson on day 1-3; Etoposide 120mg/m2 was administered intravenously over 60 minutes on days 1-4; Endostar 15 mg was administered over 90 minutes by IV infusion on days 1-14; Repeated every 3 weeks for up to four cycles.
The First College Of Clinical Medical Science, China Three Gorges University ＆Yichang Central People's Hospital; The First College Of Clinical Medical Science, China Three Gorges University, self-funded
small-cell lung cancer
 
 
ChiCTR1800015862: Different administration of Endostar Combined with Paclitaxel and Carboplatin in the Treatment of Advanced Non Small Cell Lung Cancer

Recruiting
N/A
60
 
endostar continuous intravenous infusion by pumping ;endostar normal infusion group
Fujian Cancer Hospital; Fujian Cancer Hospital, No
Advanced Non Small Cell Lung Cancer
 
 
ChiCTR-IPR-17013479: Human recombinant endostatin (Endostar) combined with concurrent radiochemotherapy in patients with Inoperable stage III non-small cell lung cancer : a prospective, randomized controlled clinical study

Not yet recruiting
N/A
120
 
Endo combined with radiotherapy and chemotherapy on the 1st, 3rd, 5th and 7th week: Endostar: 7.5 mg / m2 / d × 7 days, continuous intravenous infusion, IMRT 6 to 7 weeks after the second week Strong radiotherapy): PTV 60-66GY / 30-33 times, concurrent chemotherapy: 2, 3,4,5,6,7,8 weeks, carboplatin AUC ;radiotherapy and chemotherapy
Affiliated hospital of Zunyi Medical University; Affiliated hospital of Zunyi Medical University, This work was supported by NSFC (Natural Science Foundation of China) , Start-Up Fund for Doctor of Zunyi Medical University and the Department of Science and Technology of Guizhou Province
Inoperable stage III non-small cell lung cancer
 
 
ChiCTR1900021786: Endostar combined with GP regimen chemotherapy in the treatment of local advanced or advanced squamous cell lung carcinoma

Recruiting
N/A
200
 
;
Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology; Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology, Self-financing
Squamous Cell Lung Carcinoma
 
 
ChiCTR2000035129: A Real-world Study of Endostar Combined with Chemotherapy and Chemoradiotherapy in the Treatment of Non-Small Cell Lung Cancer and Esophageal Cancer

Recruiting
N/A
3500
 
N/A
Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Hospital; Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Hospital, N/A
Non-small Cell Lung Cancer and Esophageal Cancer
 
 
ChiCTR1900021961: A multicenter study for efficacy and safety of endostar combined with chemotherapy for the treatment of relapsed or metastasis breast cancer

Not yet recruiting
N/A
50
 
endostar plus chemotherapy
Zhejiang Cancer Hospital; Zhejiang Cancer Hospital, Self-financing
Breast cancer
 
 
ChiCTR1900023714: Prospective clinical study for recombinant human endostatin combined with total central radiotherapy for recurrent medulloblastoma in children

Not yet recruiting
N/A
20
 
endostar plus radiotherapy
Army Characteristic Medical Center (Daping Hospital); Army Characteristic Medical Center (Daping Hospital), Self-financing
Medulloblastoma
 
 
ChiCTR1900023664: Study for PD-1 Inhibitor and Endostar in Previously Treated Advanced Non–Small-Cell Lung Cancer

Not yet recruiting
N/A
50
 
PD-1 Inhibitor and Endostar
The Fifth Affiliated Hospital, Sun Yat-sen University; The Fifth Affiliated Hospital, Sun Yat-sen University, none
lung cancer
 
 
ChiCTR1900026977: A real-world study for endostar and immunotherapy combined radiotherapy in the treatment of advanced lung cancer

Not yet recruiting
N/A
20
 
endostar and immunotherapy combined radiotherapy
Department of Oncology, the Second People's Hospital of Yibin; Department of Oncology, the Second People's Hospital of Yibin, no
advanced lung cancer
 
 
SBRTLCES, NCT04274270: SBRT With S1 Combined With Endostar in the Treatment of Lung Cancer

Not yet recruiting
N/A
60
RoW
Endostar, S1
Peking University Third Hospital, Mianyang Central Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Cancer Hospital, Peking University International Hospital, China-Japan Friendship Hospital, The fifth medical center of PLA general hospital, Second Hospital of Shanxi Medical University, Hiser Medical Center of Qingdao, Guangxi Ruikang Hospital, GEM flower hospital of Liaohe oil field, Tang-Du Hospital, Third Affiliated Hospital of Guizhou Medical University, Liuzhou Worker's Hospital, The Affiliated Hospital of Xuzhou Medical University, Dalian municipal central hospital affiliated of dalian medical university
Radiotherapy Side Effect
01/22
01/23
ChiCTR1900022095: A randomized controlled study for Endostar combined with PF regimen concurrent radiotherapy compare with PF regimen concurrent radiotherapy for Advanced esophageal cancer

Not yet recruiting
N/A
120
 
Endostar+chemoradiotherapy ;chemoradiotherapy
Red Cross Hosptical of Yulin; Red Cross Hosptical of Yulin, Self financing
esophageal cancer
 
 
R-helper, NCT04161352: Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC

Not yet recruiting
N/A
500
NA
Zhejiang Cancer Hospital
Unresectable Stage III NSCLC
06/22
12/23
ChiCTR2000033949: An exploratory clinical study of endostar combined with PD-1 antibody and Platinum-based dual drug regimen in the first-line treatment of advanced or metastatic non-small cell lung cancer

Not yet recruiting
N/A
96
 
endostar combined with PD-1 antibody and Platinum-based dual drug regimen
The Fifth Affiliated Hospital of Sun Yat-Sen University; The Fifth Affiliated Hospital of Sun Yat-Sen University, No financial support
Locally advanced or metastatic non-small cell lung cancer
 
 
ChiCTR2100051606: A single arm and a clinical pilot study of Envafolimab combined with Endostar and concurrent chemoradiotherapy in the treatment of unresectable locally advanced esophageal squamous cell carcinoma

Recruiting
N/A
105
 
Radiotherapy 50.4Gy/28次 ;Envafolimab; Endostar 75mg QW
Affiliated Cancer Hospital of Shandong First Medical University; Affiliated Cancer Hospital of Shandong First Medical University, No
Esophageal Squamous Cell Carcinoma
 
 
ChiCTR1900025638: Clinical study for recombinant human endostatin combined with chemoradiotherapy for glioma

Not yet recruiting
N/A
71
 
endostar plus chemoradiotherapy
Lanzhou University Second Hospital; Lanzhou University Second Hospital, Self-financing
glioma
 
 
ChiCTR1900027462: The real world of intravenous infusion of endostar combined with first-line immunotherapy for advanced or metastasis driven gene negative NSCLC

Not yet recruiting
N/A
224
 
Endostar, PD-1/PD-L1 and conventional chemotherapy ;Endostar combined with chemotherapy
Guangxi Medical University Affiliated Tumor Hospital; Guangxi Medical University Affiliated Tumor Hospital, nothing
NSCLC
 
 
ChiCTR1900022096: A randomized controlled study for Endostar and Hyperthermia Combined with chemoradiotherapy for locally advanced esophageal cancer

Not yet recruiting
N/A
400
 
chemoradiotherapy ;Endostar Combined with chemoradiotherapy ;Hyperthermia Combined with chemoradiotherapy ;Endostar and hyperthermia Combined with chemoradiotherapy
The Second Affilicated Hosptical of Guangxi Medical University; The Second Affilicated Hosptical of Guangxi Medical University, Self financing
esophageal cancer
 
 
ChiCTR2100045038: Short-Term Efficacy of Local Iodine Pleurodesis Versus Intrapleural Perfusion of Recombinant Human Endostatin Combined with Cisplatin in the Treatment of Non-small Cell Lung Cancer Complicated With Malignant Pleural Effusion: a Randomized Clinical Study

Recruiting
N/A
152
 
Intrapleural perfusion of endostar combined with cisplatin ;Iodophor was injected into the chest
Peking University First Hospital; Peking University First Hospital, None
Malignant pleural effusion from non-small cell lung cancer
 
 
NCT05879796: Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer

Not yet recruiting
N/A
30
NA
cis-platinum, Cisplatin, radiation, External beam radiotherapy, Brachytherapy, Envafolimab Injection, KN035, Recombinant Human Endostatin Injection, endostar
Peking University Third Hospital
Cervical Cancer
05/24
05/26
ChiCTR2100054796: An exploratory single-arm clinical study of β -glucan combined with Envafolimab and Endostar as second-line treatment for advanced NSCLC after PD-1 inhibitor failure

Not yet recruiting
N/A
30
 
Beta-glucan in combination with Nvorimab and Endostat
Changzhou Second People's Hospital; Changzhou Second People's Hospital, Self-financed
Non-small cell lung cancer
 
 
ChiCTR2400088085: Efficacy and safety of intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) combined with systematic chemotherapy in osteosarcoma

Not yet recruiting
N/A
10
 
Intravenous (2-4 cycles): Methotrexate 10g/m2; Doxorubicin 60-75mg/m2 Arteries (2-4 cycles): Recombinant endostatin 150mg infused for 6 hours; Cisplatin 120mg/m2 infusion for 6 hours
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, none
osteosarcoma
 
 
ChiCTR2500100417: Efficacy and safety analysis of Endostar in cross-line therapy in patients with advanced non-small cell lung cancer

Recruiting
N/A
290
 
None. Continue Endostar antiangiogenic therapy after the first progression; None. Endostar antiangiogenic therapy is no longer used after the first progression
The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university, Beijing Life Oasis public Service Center
Non-small cell lung cancer
 
 
ChiCTR2200062942: A single-arm, exploratory trial of Envafolimab in combination with endostar and concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma

Not yet recruiting
N/A
50
 
Envafolimab in combination with endostar and concurrent chemoradiotherapy
First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Zhengzhou University, Jiangsu Simcere Pharmaceutical Co. , Ltd.
Esophageal squamous cell carcinoma
 
 
suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
SCORES, NCT04908787: A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Active, not recruiting
3
421
RoW
BD0801, Paclitaxel, Placebo, Topotecan, doxorubicin liposome
Jiangsu Simcere Pharmaceutical Co., Ltd., Shanghai Xianxiang Medical Technology Co., Ltd.
Ovarian Cancer
12/23
12/24
NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

Terminated
2
86
RoW
Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine
Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Solid Tumor
07/23
07/23
 

Download Options